STML 701-0114: A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)
Cancer - Brain
Principal Investigator: Tommy Mikkelsen, MD
The purpose of this study is to determine the safety and efficacy of SL-701 as a treatment for recurrent glioblastoma multiform (GBM).
- 18 years of age or older
- Histologically confirmed GBM or World Health Organization (WHO) Grade IV variants (gliosarcoma, glioblastoma with oligodendroglial features, or giant cell glioblastoma)
- Unequivocal evidence of a first tumor recurrence or progression on the initial treatment regimen (prior to enrollment on this study), consisting of surgical resection, radiation, and temozolomide chemotherapy, as assessed by MRI or CT scan of the brain with and without contrast within 14 days prior to the start of SL-701